Article Text
Miscellaneous
Oral gefitinib produces symptomatic and radiological benefit in advanced NSCLC
Statistics from Altmetric.com
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is one of the new biological treatments for lung cancer. EGFR mediates cancer cell growth, proliferation, invasion, and metastasis and inhibits apoptosis.
This was a multicentre trial of gefitinib in patients with symptomatic stage …